Chimerix (NASDAQ:CMRX) Shares Pass Below 200 Day Moving Average of $0.95

Chimerix, Inc. (NASDAQ:CMRX) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.95 and traded as low as $0.86. Chimerix shares last traded at $0.88, with a volume of 177,984 shares trading hands.

Wall Street Analyst Weigh In

A number of analysts have issued reports on CMRX shares. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Chimerix in a research note on Wednesday, August 14th. StockNews.com upgraded shares of Chimerix from a “sell” rating to a “hold” rating in a research report on Wednesday, August 21st. Finally, Wedbush reiterated an “outperform” rating and set a $6.00 price objective on shares of Chimerix in a research report on Tuesday, August 13th.

Chimerix Stock Performance

The firm has a fifty day simple moving average of $0.90 and a 200 day simple moving average of $0.95. The company has a market capitalization of $78.43 million, a PE ratio of -0.94 and a beta of 1.12.

Chimerix (NASDAQ:CMRX) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.23) EPS for the quarter, meeting the consensus estimate of ($0.23). Chimerix had a negative net margin of 25,337.96% and a negative return on equity of 46.35%. The business had revenue of $0.13 million during the quarter, compared to analyst estimates of $1.26 million. During the same quarter in the previous year, the business posted ($0.21) EPS. Research analysts expect that Chimerix, Inc. will post -0.86 EPS for the current fiscal year.

Hedge Funds Weigh In On Chimerix

A number of large investors have recently made changes to their positions in CMRX. Koshinski Asset Management Inc. acquired a new stake in Chimerix in the 1st quarter worth approximately $42,000. Marquette Asset Management LLC lifted its stake in shares of Chimerix by 24.3% during the first quarter. Marquette Asset Management LLC now owns 116,009 shares of the biopharmaceutical company’s stock worth $123,000 after buying an additional 22,709 shares during the period. Marshall Wace LLP purchased a new stake in shares of Chimerix during the second quarter valued at $137,000. Pale Fire Capital SE increased its position in shares of Chimerix by 113.6% in the 4th quarter. Pale Fire Capital SE now owns 211,214 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 112,318 shares during the period. Finally, Vestal Point Capital LP purchased a new position in Chimerix in the 4th quarter worth $1,348,000. 45.42% of the stock is owned by institutional investors and hedge funds.

Chimerix Company Profile

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.